|
PTIX | Protagenic Therapeutics, Inc.new |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.65 |
| Leverage | 38.36% |
| Market Cap | $ 2.7m |
| PE | 6.53 |
| Dividend Yield | 0.00% |
| Profit | $ 407.4k |
| Margin | 8.82% |
Protagenic Therapeutics, Inc., a preclinical biopharmaceutical company, is dedicated to the discovery and development of therapies to treat stress-related mood and neuropsychiatric disorders. The company is headquartered in New York, New York.